FGFR4 and cancer: From such, many pharmaceutical companies have developed treatments that may target cancer cells that use FGFR4/βK overexpression as a mechanism for chemotherapeutic resistance, developing pan-FGFR inhibitors and selective FGFR4 inhibitors.691,692 Similar to other cases of chemotherapeutic resistance, mutations have been found in FGFR4 such as FGFR4-V550L or FGFR4-V550M which limit the design and applicability of current FGFR4 antagonists.